Actavis Group hf

SUNNYVALE, Calif., Jan. 31, 2024 /PRNewswire/ - Willow Biosciences Inc. (" Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, today announced a collaboration with a leading Active Pharmaceutical Ingredient ("API") manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally. Willow's collaboration partner, who currently holds a significant world market share of the API market, recognized the need to employ more sustainable methods to manufacture its APIs with reduced cost and less waste and sought Willow's expertise in developing and scaling a manufacturing process for this key ingredient. The new partnership program will focus on optimization of an existing commercial biomanufacturing process for improved performance at scale. The development phase of this funded collaboration is expected to last approximately six months with additional milestone payments to be made for achieving defined performance targets. "We are excited to once again apply our technology platform to the manufacture of more sustainable APIs for existing, large volume global markets," said Dr. Chris Savile, Willow's President & CEO. "If successful, we believe that these ingredients essential for human health can be made more broadly available and more efficiently while also delivering significant value to our partner and shareholders." This agreement represents the second new development agreement executed by Willow in only the first few weeks of 2024, with a robust pipeline of other potential collaborations in process. About Willow Biosciences Inc. Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit . FutureGrown™ and BioOxi™ are registered trademarks of Willow Biosciences Inc. All other trademarks are trademarks of their respective holders. Forward-Looking Statements This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations, and, more particularly, statements concerning: the development programs with its biopharma partner, including the ability to accommodate new programs and to expand capabilities;; the demand and market size potential of the synthetic ingredients industry; and the business plan of the Company, generally, including becoming a leader in precision fermentation, research and production of functional ingredients. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the development of future strategic partnerships; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results biotechnology industry in general; the success of the Company's research and development strategies; infringement on intellectual property; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; competition from other industry participants; adverse U.S., Canadian and global economic conditions; adverse global events and public-health crises,; failure to comply with certain regulations; departure of key management personnel or inability to attract and retain talent; and other factors more fully described from time to time in the reports and filings made by the Company with securities regulatory authorities. Please refer to the Company's most recent annual information form and management's discussion and analysis for additional risk factors relating to Willow, which can be accessed either on Willow's website at or under the Company's profile on . The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement. SOURCE Willow Biosciences Inc.

Grants, New Mexico, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) today announced the agreement to purchase assets from C2 Wellness Corporation. (“C2”), a Wyoming registered company with an address at 30 N Gould St, Ste R, Sheridan, WY, that owns certain platform technologies and associated intellectual property invented and developed by the scientific team of C2. The purchase is for 5 million shares of common stock of Bright Green Corporation payable to all shareholders of C2. The implementation of the transaction has been approved by the board of both companies. The primary assets relate to: Novel cannabinoid molecules and their associated intellectual property;Novel cannabinoid prodrugs, and their associated intellectual property;Novel proprietary cannabinoid formulations, designed to target lymphatic delivery, and their associated intellectual property;Novel proprietary nano-encapsulated cannabinoid formulations, in self dissolving polymers, and their associated intellectual property; andCannabinoids and cannabinoid pro-drug formulations for topical ocular delivery, and their associated intellectual property. Along with the technology platforms and associated intellectual property come the scientific team of C2 and relationships with universities and a number of renowned academics worldwide. “This acquisition and strategic partnership signifies a major advancement in plant-based drug development and solutions that not only enhance health and wellness, but also create significant value for the shareholders of both Bright Green and C2. This groundbreaking collaboration involves the acquisition of innovative CBD and THC-based molecules from C2 Wellness Corp by Bright Green Corporation,” said Lynn Stockwell. Dr. Emmanuel Dumont, PhD, Senior Advisor to C2 Wellness Corp and is Associate Professor at Georgetown University co appointed with Hackensack Meridian Health Medical School -New Jersey and Associate Professor at the Center for Discovery and Innovation - Nutley, New Jersey where he is working among other tasks, on large -Language Models ( LLM) perfecting an AI Conversational Doctor able to conduct differential diagnoses and evaluate the emergency severity index of conditions. He is a distinguished biotechnology expert, emphasises the importance of this alliance: "This collaboration with Bright Green Corporation is a testament to our dedication to leading in plant-based drug discovery and development. With my expertise in securing research funding, we are set to innovate CBD and THC analogs with enhanced properties, derived exclusively from plant sources. Our focus is on developing products that offer improved safety and efficacy over current CBD and THC-based medicines (Epidiolex® and Sativex®), aiming for superior patient outcomes with an addressable market of nearly $756 million. The partnership will capitalise on the 'Drugs Made in America' initiative by Bright Green Corporation. The Active Pharmaceutical Ingredients (APIs) for the synthesis of CBD and THC analogs will be produced at Bright Green Corporation’s facility in Grants, with research and development activities taking place at a cutting-edge research center in Albuquerque, New Mexico. By employing proprietary artificial intelligence and machine learning tools, the partnership is geared towards designing novel CBD and THC analogs with improved pharmacological properties, marking a significant stride in plant-based medicine development. Mr. Groovy Singh, CEO of Bright Green Corporation, stated, “Our collaboration with C2 and its scientific team strongly demonstrates our commitment to scientific research and innovation while simultaneously bolstering the management team, a key goal of ours in 2024." Media Inquiries & Investor Relations Contactir@brightgreen.us About Bright Green Bright Green is one of the first companies selected and approved by the US government to legally grow, manufacture, and sell cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export under legal and state law. Our approval, based on pre-agreed terms set by the U.S. Drug Enforcement Administration, gives Bright Green the opportunity to advance the vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us. Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control, including but not limited to, the inability of the Company to raise funds under the Company’s EB-5 program, and the impact that new officers, directors and employees may have on the Company and the Company’s business and results of operations. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as amended and supplemented, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the Company’s results is included in the Company’s SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov.

OTAWA,ON, Nov. 6, 2023 /PRNewswire/ -- The active pharmaceutical ingredients (API) market size was valued at USD 204.04 billion in 2023 and likely to hit around USD 363.68 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. An active pharmaceutical ingredient (API) is a drug's active component. API is an element of any medication that produces the expected effects. Medicines are usually made up of several constituents, and the essential part is the API. Excipients are other ingredients needed to be biologically harmless and commonly form a volatile portion of the drug result. Some drugs include active APIs to treat multiple symptoms or act in complex ways. Regional pharmaceutical firms have done the bulk of API preparation. The API market was valued at 186.12 billion in 2020 and is expected to grow at a CAGR of 6.0%. Advancements in Active Pharmaceutical Ingredient (API) manufacturing, growth of biopharmaceutical sector, and increase in geriatric population are among key drivers of market growth. Rising prevalence of chronic diseases, such as cardiovascular diseases and cancer, is anticipated to boost the market growth. Full Study is Ready | Get the sample pages of report@ Data and statistics Active Pharmaceutical Ingredients Market The Department of Pharmaceuticals, India, has offered approval for bulk drug manufacturing in Himachal Pradesh, Andhra Pradesh and Gujrat under 'Promotion of Bulk Drug Parks' scheme that offers financial aids to capitalize the nation's active pharmaceutical ingredient production. Under the scheme, the government of Assam has estimated a pharmaceutical park with an investment of Rs.153.64 crores. In 2023, Boehringer Ingelheim invested $315 million in its new manufacturing facility for active pharmaceutical ingredients in Germany. In FY23, the drug export in India increased by 3.25% to $25.3 billion, according to the report by the Pharmaceuticals Export Promotion Council of India. In FY2022, the United States, UK and Russia were major export destinations for India's pharma industry; the United States held 29% share. With the emergence of generic medicines after the pandemic, the US Food and Drug Administration has witnessed 17% growth (as compared to 2022) in Drug Master Files (DMFs) submission. In the first half of 2023, a total of 410 Type II DMFs were submitted. China's submission of DMFs in the same period increased by 46.5% In 2023, Canadian government invested $80.5 million in federal funding to support Canadian Critical Drug Initiative for next five years. Under the initiative, Canada aims to create a robust manufacturing facility to develop approximately 70 million doses of critical medicines each year. The Government of India has started Production Linked Incentives (PLIs) scheme in order to supprot the domestic manufacturing of active pharmaceutical ingredients; the government has also approved an investment of $812 million for pharmaceutical and medical device manufacturing. A major manufacturer of API in India, Reddy's Laboratories Ltd. witnessed a 3% year-on-year growth in its pharmaceutical services and active pharmaceutical ingredients segment for the final quarter of 2023. Industry major Evonik invested €25 million to expand its manufacturing capacity for active pharmaceutical ingredients in Germany. The entire expansion project is aimed to be finalized by 2024. Evonik, in 2022, invested $220 million under a partnership with the US government for a new production facility. Tippecanoe is the chosen location for the new facility, which is the world's largest site for active pharmaceutical ingredients. Drug major Cipla, India, witnessed a 43.4% growth in its consolidated net profit (for the quarter ended in September 2023). While focusing on its active pharmaceutical ingredients' facilities, the company has stated its plans of capital expenditure worth ₹1,500 crore. Synthetic API market dominated the overall market in 2020 in terms of revenue share of 71.91%. Biotech molecule is expected to be the fastest growing segment and is anticipated to grow at a lucrative CAGR of 6.2% during the forecast period. Biotech molecule segment is driven by factors such as increasing demand for biopharmaceuticals and higher efficiency of these molecules. Rising R&D investments are also crucial for segment growth owing to development of highly potent molecules that can generate higher revenue. Active Pharmaceutical Ingredient (API) Market Size, By Types of Synthesis, 2022-30 (US$ Billion) Captive API market dominated the overall market in 2020 in terms of revenue share of 57.44%, owing to higher availability of raw materials and intensive capitalization of major key players in development of high-end manufacturing facilities. Merchant API market is expected to be the fastest growing segment and is expected to grow at a lucrative CAGR of 6.1% during the forecast period. Merchant, i.e., outsourcing market is driven by factors such as rising demand for biopharmaceuticals and high cost of in-house manufacturing of these molecules. The share of merchant API market is expected to increase from 42.56% in 2020 to 43.17% by 2030. Active Pharmaceutical Ingredient (API) Market Size, By Types of Manufacturers 2022-30 (US$ Billion) Innovative API dominated the market in 2022, but the growth is expected to slow down in the coming decade owing to patent expirations and decrease in revenue. However, generic API will overtake the branded market owing to exponential growth of generic industry in regions such as India and China. Regional government support is another factor improving the growth rate of generic APIs. Customize this study as per your requirement@ Active Pharmaceutical Ingredient (API) Market Size, By Types, 2022-30 (US$ Billion In 2022, North America was the largest market for APIs due to established branded drug industry in the U.S. Moreover, growing R&D initiatives aid in availing capital for new molecule development. Asia Pacific is expected to be the fastest growing market over the forecast period. Availability of affordable labor and presence of major companies in the industry that are setting up API manufacturing plants in developing counties such as China & India. Government support for setting up new facilities in countries such as the U.S. and India is a driver for manufacturers to expand their businesses. Regional Snapshot North America is expected to retain the largest share in the active pharmaceutical ingredient (API) market over the forecast term. This is imputable to the growth in occurrences of chronic diseases and the emerging need for speciality drugs in the area. Furthermore, the growing significance of generics and Investments in feasible proof by pharmaceutical firms is also projected to aid the development of the active pharmaceutical ingredient (API) market soon. Active Pharmaceutical Ingredient (API) Market Share, By Region, 2021-30 (%) Europe has anticipated expanding significantly in the global active pharmaceutical ingredient (API) market and will probably carry on the same fashion over the forecast period. This is attributable to the increase in investment in research and development activities and the regional market in the region. Moreover, the rise in biopharmaceutical firms is also projected to help the regional advancement of the market. The U.S. active pharmaceutical ingredients market was accounted for USD 34.90 billion in 2022 and will reach at a CAGR of 6.8% from 2023 to 2030. The Canada active pharmaceutical ingredients market was accounted for USD 26.72 billion in 2022 and will reach at a CAGR of 5.9% from 2023 to 2030. The Mexico active pharmaceutical ingredients market was accounted for USD 16.45 billion in 2022 and will reach at a CAGR of 4.9% from 2023 to 2030. Report Highlights The COVID-19 outbreak had a positive crash on the worldwide APIs market. The drug-induced industry was an epicentre in therapy symptoms linked to COVID-19, including cough, high fever, and cold. Due to the rising popularity of the drug industry during the pandemic, the active pharmaceutical ingredients market has also seen growth over time. However, the coronavirus outbreak has caused global business and economic disturbance. APIs are utilized as Antibody Drug Conjugates (ADCs). They are significant and efficient care modalities combined with organically drugs and antibodies for cancer treatment. APIs aim for cancer cells when they generate the least disclosure of drugs. Hence, the progress of cancer-specific APIs is predicted to increase the API market growth. The critical element scaling up the expansion of the active pharmaceutical ingredients market is the emerging drug exploration and progress activities for drug making, the rising significance of generics, and the growing intake of biopharmaceuticals. Even so, the adverse drug cost command approach throughout numerous nations and high making prices are projected to hamper the market's advancement. Furthermore, introducing new drugs, cooperation, and geographical expansions are some of the firms' strategic initiatives to hold constancy in the market. This is probably to fuel market expansion in the forthcoming. The active pharmaceutical ingredients (API) market has typically been labelled by drugs, like cardiovascular, anti-infectives and diabetes, pain management drugs, and analgesics. Thereby, per the research and development trends, the need is shifting toward expanding complicated APIs used in new formulations, aiming for niche therapeutic aspects. The significant elements confining the market growth include: Drug price control policies throughout various countries. Vicious contests amongst existent players. Stringent regulative guidelines. Market Dynamics Market Drivers The increasing consent in Abbreviated New Drug Applications (ANDA) raises the need for active pharmaceutical ingredients (API). A company must file an Abbreviated New Drug Application (ANDA) to market a generic drug. An ANDA authorization means that the generic drugs is reasonably comparable to the original prescription regarding the quality, route of administration, dosage form, strength, performance characteristics, and intended use. Therefore, these acceptances favour quicker approval of APIs. The rise in the prevalence of chronic disorders boosts the market. Besides cancer, many other diseases have exhibited increasing occurrence rates. Therefore, these increasing chronic disease cases augment the market's requirement and expansion. Market Restraints Numerous firms can only produce a drug if the patent of a drug is terminated, and late approvals from the companies hamper the market growth. The demand for high capital for the manufacturing of APIs as the process requires highly systematic protocols resulting in the outsourcing of various APIs. Low and middle economic countries need help to afford it. Thereby, the need for low-cost substitutes is more in satisfactory-income countries in Asia Pacific, Africa, and Latin America. The unavailability of appropriate care affects market growth. Market Opportunities Some drugs addressed to an API may be a bulk-finished commodities. Moreover, active pharmaceutical ingredients have pulled significant consideration from regulative bodies on a global scale as it provides safety care. Higher approval of synthetic API is escalating the market growth. Highly potent active pharmaceutical ingredients specify a massive transfer as pharmaceutical firms use small molecules to render new medicines. Its advantages include the demand for a lower therapeutic dose, the ability to bind to particular receptors, and high efficiency can be recognized as a growing need amongst producers and consumers. Numerous API manufacturers have approved highly potent active pharmaceutical ingredients to distinguish themselves from the competition as the generic API industry gradually competes, boosting the market growth. Market Challenges The expensive expenditure in their manufacturing cells encompasses: Renovation of production accommodations. Compilation of a portfolio of commodity security and efficiency tests. Familiarizing staff with skill norms. Furthermore, acquiring regulatory clearances is more expensive for small businesses. The high manufacturing costs are a substantial dispute for the growing active pharmaceutical ingredients market in the forthcoming years. Precedence Statistics is one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Recent Developments In 2021, Reddy's Laboratories Ltd advertised the opening of Reddy-Lenalidomide, a generic which is an alternative to Revlimid capsules, authorized by Health Canada for the therapy of transfusion-dependent anaemia. In 2021, Teva Pharmaceutical and MEDinCell were sanctioned by the United States Food and Drug Administration (FDA) for a Novel Drug Request for TV-46000/mdc-IRM. The medication is being utilized to cure schizophrenia. In 2021, Novasep devoted roughly EUR 6 million to its Chasse-sur-Rhône, France site to improve its potential in spaces like central nervous system (CNS), oncology, and infectious diseases. In 2020, Pfizer signed a deal with Gilead Sciences to produce and provide Gilead's virus scan drug termed Remdesivir for the care of COVID-19 long term. Related Reports High Potency Active Pharmaceutical Ingredients Market - The market size was valued at USD 24.28 billion in 2022 and expanding around USD 55.66 billion by 2032 with a CAGR of 8.7% from 2023 to 2032. Small Molecule API Market - The market size was estimated at USD 176 billion in 2022 and is expanding around USD 299.2 billion by 2032 with a CAGR of 5.5% from 2023 to 2032. Healthcare API Market - The market size was valued at USD 218.41 million in 2022 and is expanding around USD 309.86 million by 2032 with a CAGR of 3.56% from 2023 to 2032. Plant-based API Market - The market size was valued at USD 30.12 billion in 2022 and it is expanding around USD 56.12 billion by 2032 with a CAGR of 6.42% from 2023 to 2032. API Management Market - The global API management market size was valued at USD 5.07 billion in 2022 and is expanding around USD 94.27 billion by 2032 with a CAGR of 34% from 2023 to 2032. Telecom API Market - The market size was valued at USD 206.14 billion in 2021 and is expanding around USD 1.2 trillion by 2030 with a CAGR of 21.62% from 2022 to 2030. Key Market Players Albemarle Corporation AurobindoPharma Reddy's Laboratories Ltd AbbVieInc Teva Pharmaceutical Industries Ltd Mylan N.V. CiplaInc BoehringerIngelheim International GmbH Merck & Co., Inc Sun Pharmaceutical Industries Ltd Bristol-Myers Squibb Company Novartis AG Market Segmentation By Type of Synthesis Biotech Monoclonal Antibodies Recombinant Proteins Vaccines Synthetic By Type of Manufacturer Captive APIs Merchant APIs Generic APIs Innovative APIs By Type Generic APIs Innovative APIs By Type of Drug Prescription Drugs Over-the-counter Drugs By Application Cardiovascular Diseases Oncology CNS & Neurological Disorders Orthopedic Disorders Endocrinology Pulmonology Gastrointestinal Disorders Nephrology Ophthalmology Others By Geography North America Europe Asia-Pacific Latin America Middle East & Africa (MEA) Immediate Delivery Available | Buy This Premium Research Report@ About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us: For more details Contact: [email protected] USA - +1 9197 992 333 | IND - +91 93077 85324 | +1 9197 992 333 Logo: SOURCE Precedence Research